In This Article:
As global markets exhibit mixed signals with some regions showing growth while others face economic slowdowns, the Swedish stock market presents unique opportunities for investors looking for value. In such a landscape, identifying stocks that trade below their estimated intrinsic values could offer potential for substantial returns.
Top 10 Undervalued Stocks Based On Cash Flows In Sweden
Name | Current Price | Fair Value (Est) | Discount (Est) |
Bj?rn Borg (OM:BORG) | SEK54.90 | SEK102.16 | 46.3% |
Arcoma (OM:ARCOMA) | SEK18.00 | SEK35.84 | 49.8% |
Boule Diagnostics (OM:BOUL) | SEK10.60 | SEK21.00 | 49.5% |
Biotage (OM:BIOT) | SEK155.80 | SEK297.39 | 47.6% |
Nordic Waterproofing Holding (OM:NWG) | SEK161.00 | SEK296.94 | 45.8% |
Net Insight (OM:NETI B) | SEK4.93 | SEK9.85 | 50% |
Nolato (OM:NOLA B) | SEK56.95 | SEK111.50 | 48.9% |
MilDef Group (OM:MILDEF) | SEK69.60 | SEK132.41 | 47.4% |
Humble Group (OM:HUMBLE) | SEK10.42 | SEK19.62 | 46.9% |
Gigasun (OM:GIGA) | SEK3.85 | SEK7.51 | 48.7% |
We'll examine a selection from our screener results
Biotage
Overview: Biotage AB (publ) specializes in providing solutions and products for drug discovery and development, analytical testing, as well as water and environmental testing, with a market capitalization of SEK 12.47 billion.
Operations: The company generates SEK 1.98 billion in revenue from its healthcare software segment.
Estimated Discount To Fair Value: 47.6%
Biotage, priced at SEK 155.8, is significantly undervalued based on a DCF valuation of SEK 297.39, trading 47.6% below its estimated fair value. Despite a recent dip in net income and EPS as reported in Q1 2024 results, Biotage's earnings are expected to grow by approximately 20% annually over the next three years, outpacing the Swedish market's average. Revenue growth projections also exceed market trends at an annual rate of 11.2%, highlighting potential for appreciation despite current financial inconsistencies.
Nolato
Overview: Nolato AB specializes in developing, manufacturing, and selling plastic, silicone, and thermoplastic elastomer products across various sectors including medical technology, pharmaceuticals, consumer electronics, and automotive. The company operates globally with a market capitalization of SEK 15.34 billion.
Operations: The revenue for the Medical Solutions segment is SEK 5.34 billion.
Estimated Discount To Fair Value: 48.9%